EE200000504A - Bensofurüül-a-pürooni derivaadid, farmatseutilinekompositsioon, lipiidide ainevahetuse kiirendaja,triglütseriidi biosünteesi inhibiitor, vere triglütseriiditaset alandav toimeaine, vere HDL taset tõstev toimeaine, arterioskleroosi profülaktiline to - Google Patents

Bensofurüül-a-pürooni derivaadid, farmatseutilinekompositsioon, lipiidide ainevahetuse kiirendaja,triglütseriidi biosünteesi inhibiitor, vere triglütseriiditaset alandav toimeaine, vere HDL taset tõstev toimeaine, arterioskleroosi profülaktiline to

Info

Publication number
EE200000504A
EE200000504A EEP200000504A EEP200000504A EE200000504A EE 200000504 A EE200000504 A EE 200000504A EE P200000504 A EEP200000504 A EE P200000504A EE P200000504 A EEP200000504 A EE P200000504A EE 200000504 A EE200000504 A EE 200000504A
Authority
EE
Estonia
Prior art keywords
blood
triglyceride
benzofuryl
arteriosclerosis
agent
Prior art date
Application number
EEP200000504A
Other languages
English (en)
Estonian (et)
Inventor
raviaine
Naniwa Yoshimitsu
Imai Hiroshi
Ida Tomohide
Muratani Emiko
Kitai Kazuo
Sugimoto Yoshinori
Kosugi Tomomi
Takeuchi Akiko
Watanabe Kunihito
Tomiyama Takami
Takeuchi Tomio
Hamada Masa
Original Assignee
Teijin Limited
Microbial Chemistry Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Limited, Microbial Chemistry Research Foundation filed Critical Teijin Limited
Publication of EE200000504A publication Critical patent/EE200000504A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • External Artificial Organs (AREA)
  • Luminescent Compositions (AREA)
EEP200000504A 1998-03-12 1999-03-12 Bensofurüül-a-pürooni derivaadid, farmatseutilinekompositsioon, lipiidide ainevahetuse kiirendaja,triglütseriidi biosünteesi inhibiitor, vere triglütseriiditaset alandav toimeaine, vere HDL taset tõstev toimeaine, arterioskleroosi profülaktiline to EE200000504A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6135698 1998-03-12
PCT/JP1999/001225 WO1999046262A1 (en) 1998-03-12 1999-03-12 Benzofurylpyrone derivatives

Publications (1)

Publication Number Publication Date
EE200000504A true EE200000504A (et) 2002-02-15

Family

ID=13168805

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000504A EE200000504A (et) 1998-03-12 1999-03-12 Bensofurüül-a-pürooni derivaadid, farmatseutilinekompositsioon, lipiidide ainevahetuse kiirendaja,triglütseriidi biosünteesi inhibiitor, vere triglütseriiditaset alandav toimeaine, vere HDL taset tõstev toimeaine, arterioskleroosi profülaktiline to

Country Status (25)

Country Link
US (2) US6589984B1 (de)
EP (1) EP1063235B1 (de)
JP (1) JP3922884B2 (de)
KR (1) KR100595332B1 (de)
CN (1) CN1170827C (de)
AT (1) ATE266659T1 (de)
AU (1) AU756965B2 (de)
BG (1) BG104761A (de)
BR (1) BR9908706A (de)
CA (1) CA2323456A1 (de)
DE (1) DE69917237T2 (de)
EE (1) EE200000504A (de)
HR (1) HRP20000600A2 (de)
HU (1) HUP0101381A3 (de)
ID (1) ID27511A (de)
IL (1) IL138279A0 (de)
IS (1) IS5617A (de)
NO (1) NO20004517L (de)
NZ (1) NZ506802A (de)
PL (1) PL343419A1 (de)
RU (1) RU2199536C2 (de)
SK (1) SK13412000A3 (de)
TR (1) TR200002642T2 (de)
UA (1) UA58587C2 (de)
WO (1) WO1999046262A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1063235B1 (de) * 1998-03-12 2004-05-12 Teijin Limited Benzofurylpyron-derivate
WO2002020500A2 (en) * 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
DE10115408A1 (de) 2001-03-29 2002-10-02 Bayer Ag Benzofuran-Derivate
MXPA04007809A (es) * 2002-02-25 2004-10-15 Kudos Pharm Ltd Piranonas utiles como inhibidores de ataxia-telangetaxia mutada.
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
FR2929276B1 (fr) * 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
DE102014214016A1 (de) 2014-07-18 2015-11-05 Deutsches Zentrum für Luft- und Raumfahrt e.V. Leichtbaustruktur und Verfahren zur Herstellung einer Leichtbaustruktur
US11433047B2 (en) 2015-10-09 2022-09-06 Neurotheryx Canada Ltd. Pharmaceutical compositions comprising one or more pyrone compounds, and their use for treating inflammatory and neurodegenerative diseases
BR112021002207A2 (pt) 2018-08-10 2021-05-04 Diapin Therapeutics, Llc tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668803A (en) * 1984-05-10 1987-05-26 Atlantic Richfield Company Benzafuran derivatives
US4688803A (en) * 1984-06-25 1987-08-25 Ollington Robert F Casino game table and dice
RU2045529C1 (ru) * 1988-04-26 1995-10-10 Ниссан Кемикал Индастриз Лтд. Способ получения мевалонолактоновых производных
DE4308451A1 (de) * 1992-09-10 1994-04-14 Bayer Ag 3-Aryl-pyron-Derivate
ZA938019B (en) 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
US5808062A (en) 1993-11-19 1998-09-15 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
EP1063235B1 (de) * 1998-03-12 2004-05-12 Teijin Limited Benzofurylpyron-derivate

Also Published As

Publication number Publication date
KR20010041776A (ko) 2001-05-25
KR100595332B1 (ko) 2006-07-03
NO20004517D0 (no) 2000-09-11
SK13412000A3 (sk) 2001-04-09
WO1999046262A1 (en) 1999-09-16
HRP20000600A2 (en) 2001-06-30
HUP0101381A2 (hu) 2002-05-29
AU3277399A (en) 1999-09-27
US20030186976A1 (en) 2003-10-02
DE69917237D1 (de) 2004-06-17
RU2199536C2 (ru) 2003-02-27
ID27511A (id) 2001-04-12
CN1170827C (zh) 2004-10-13
CA2323456A1 (en) 1999-09-16
NO20004517L (no) 2000-09-11
IL138279A0 (en) 2001-10-31
ATE266659T1 (de) 2004-05-15
EP1063235B1 (de) 2004-05-12
AU756965B2 (en) 2003-01-30
US6589984B1 (en) 2003-07-08
BR9908706A (pt) 2000-11-21
PL343419A1 (en) 2001-08-13
UA58587C2 (uk) 2003-08-15
EP1063235A1 (de) 2000-12-27
EP1063235A4 (de) 2003-01-07
BG104761A (en) 2001-08-31
HUP0101381A3 (en) 2002-06-28
JP3922884B2 (ja) 2007-05-30
CN1299359A (zh) 2001-06-13
IS5617A (is) 2000-09-08
DE69917237T2 (de) 2005-05-04
NZ506802A (en) 2002-11-26
TR200002642T2 (tr) 2001-01-22

Similar Documents

Publication Publication Date Title
DE69917237D1 (de) Benzofurylpyron-derivate
LU91943I2 (fr) Tafluprost et ses dérivés pharmaceutiquement acceptables (SAFLUTAN®)
ATE161848T1 (de) Glycyrrheticsäurederivate
AU522926B2 (en) Xanthone and thioxanthone derivatives
NO166940C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4 (5)-substituerte imidazol-derivater, og mellomprodukttil bruk ved fremstillingen.
NO942309L (no) 5-amino-8-methyl-7-pyrrolidinylkinolin-3-carboxylsyrederivater
ATE109770T1 (de) Derivate der coffeinsäure und pharmazeutische zusammensetzungen, die sie enthalten.
NO177995C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 1,3-dioksanderivater
AU7733491A (en) Isochromane derivatives
CA2225780A1 (fr) Nouveaux derives de n-benzylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE96800T1 (de) Macrolid-derivate.
NZ220294A (en) Heteropolycyclic aromatic amines and pharmaceutical compositions thereof
SE8703494D0 (sv) Mellanprodukter anvendbara vid framstellning av 2-tiofen-ettiksyraderivat
RU95107150A (ru) Производные пиридобензоксадиазинкарбоновой кислоты, смесь их изомеров или отдельные изомеры, их фармацевтически используемые гидраты и соли, промежуточные продукты для их получения, а также фармацевтическая композиция с антибактериальной активностью на их основе
TW353071B (en) Chromene compounds with neutroleptic activity, their preparation and pharmaceutical compositions